These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 36902656)

  • 21. Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study.
    De Caterina R; Kelly P; Monteiro P; Deharo JC; de Asmundis C; López-de-Sá E; Weiss TW; Waltenberger J; Steffel J; de Groot JR; Levy P; Bakhai A; Zierhut W; Laeis P; Reimitz PE; Kirchhof P;
    J Cardiovasc Med (Hagerstown); 2019 Feb; 20(2):97-104. PubMed ID: 30540648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48.
    Bonaca MP; Antman EM; Cunningham JW; Wiviott SD; Murphy SA; Halperin JL; Weitz JI; Grosso MA; Lanz HJ; Braunwald E; Giugliano RP; Ruff CT
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep; 8(7):695-706. PubMed ID: 34962979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis.
    Wang Y; Li L; Wei Z; Lu S; Liu W; Zhang J; Feng J; Wang D
    Medicines (Basel); 2023 Jan; 10(1):. PubMed ID: 36662497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Impact of Weight on Clinical Outcomes of Edoxaban Therapy in Atrial Fibrillation Patients Included in the ETNA-AF-Europe Registry.
    Boriani G; De Caterina R; Manu MC; Souza J; Pecen L; Kirchhof P
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34209595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
    Diemberger I; Fumagalli S; Mazzone AM; Bakhai A; Reimitz PE; Pecen L; Manu MC; Gordillo de Souza JA; Kirchhof P; De Caterina R
    Europace; 2022 Oct; 24(9):1404-1411. PubMed ID: 35512229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Edoxaban vs. Vitamin K Antagonist for Atrial Fibrillation After Transcatheter Aortic Valve Replacement in Japanese Patients　- A Subanalysis of the ENVISAGE-TAVI AF Trial.
    Watanabe Y; Hayashida K; Yamamoto M; Yamanaka F; Yamasaki K; Naganuma T; Ohno Y; Yamawaki M; Morioka N; Mizutani K; Tada N; Ueno H; Nishina H; Izumo M; Nakajima Y; Ando K; Takagi K; Kimura T; Sugio K; Dangas G; Van Mieghem NM; Hengstenberg C; Chen C; Jin J; Unverdorben M; Saito S
    Circ J; 2022 Oct; 86(11):1756-1763. PubMed ID: 35965066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data.
    Warkentin L; Hueber S; Deiters B; Klohn F; Kühlein T
    Thromb J; 2022 May; 20(1):31. PubMed ID: 35619140
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.
    Skjøth F; Larsen TB; Rasmussen LH; Lip GY
    Thromb Haemost; 2014 May; 111(5):981-8. PubMed ID: 24577485
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation.
    Lee SR; Choi EK; Park SH; Jung JH; Han KD; Oh S; Lip GYH
    Eur Heart J Cardiovasc Pharmacother; 2021 Sep; 7(5):415-423. PubMed ID: 33471125
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prevalence and risk of inappropriate dosing of direct oral anticoagulants in two Swiss atrial fibrillation registries.
    Montrasio G; Reiner MF; Wiencierz A; Aeschbacher S; Baumgartner C; Rodondi N; Kühne M; Moschovitis G; Preiss H; Coslovsky M; De Perna ML; Bonati LH; Conen D; Osswald S; Beer JH; Koepfli P;
    Vascul Pharmacol; 2022 Dec; 147():107120. PubMed ID: 36182083
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study.
    Grymonprez M; De Backer TL; Bertels X; Steurbaut S; Lahousse L
    Front Pharmacol; 2023; 14():1125576. PubMed ID: 36817122
    [No Abstract]   [Full Text] [Related]  

  • 32. Non-Vitamin K Antagonist Oral Anticoagulant Dosing in Patients With Atrial Fibrillation and Renal Dysfunction.
    Yao X; Shah ND; Sangaralingham LR; Gersh BJ; Noseworthy PA
    J Am Coll Cardiol; 2017 Jun; 69(23):2779-2790. PubMed ID: 28595692
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness and safety of edoxaban therapy in daily-care patients with atrial fibrillation. Results from the DRESDEN NOAC REGISTRY.
    Köhler C; Tittl L; Marten S; Naue C; Spindler M; Stannek L; Fache K; Beyer-Westendorf J
    Thromb Res; 2022 Jul; 215():37-40. PubMed ID: 35623105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Edoxaban in Asian Patients With Atrial Fibrillation: Effectiveness and Safety.
    Lee SR; Choi EK; Han KD; Jung JH; Oh S; Lip GYH
    J Am Coll Cardiol; 2018 Aug; 72(8):838-853. PubMed ID: 30115222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-Term Clinical Outcomes of Underdosed Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Atrial Flutter.
    Ashraf H; Agasthi P; Shanbhag A; Mehta RA; Rattanawong P; Allam M; Pujari SH; Mookadam F; Freeman WK; Srivathsan K; Sorajja D; Shen WK; Noseworthy PA; Yang EH; Masry HZE; Yao X; Mulpuru SK; Beohar N; Holmes DR; Arsanjani R
    Am J Med; 2021 Jun; 134(6):788-796. PubMed ID: 33444586
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of 15-mg Edoxaban on Clinical Outcomes in 3 Age Strata in Older Patients With Atrial Fibrillation: A Prespecified Subanalysis of the ELDERCARE-AF Randomized Clinical Trial.
    Kuroda M; Tamiya E; Nose T; Ogimoto A; Taura J; Imamura Y; Fukuzawa M; Hayashi T; Akao M; Yamashita T; Lip GYH; Okumura K
    JAMA Cardiol; 2022 Jun; 7(6):583-590. PubMed ID: 35416910
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Edoxaban vs. warfarin in vitamin K antagonist experienced and naive patients with atrial fibrillation†.
    O'Donoghue ML; Ruff CT; Giugliano RP; Murphy SA; Grip LT; Mercuri MF; Rutman H; Shi M; Kania G; Cermak O; Braunwald E; Antman EM
    Eur Heart J; 2015 Jun; 36(23):1470-7. PubMed ID: 25687352
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Label Adherence for Non-Vitamin K Antagonist Oral Anticoagulants in a Prospective Cohort of Asian Patients with Atrial Fibrillation.
    Lee SR; Lee YS; Park JS; Cha MJ; Kim TH; Park J; Park JK; Lee JM; Kang KW; Shim J; Uhm JS; Kim J; Kim C; Kim JB; Park HW; Joung B; Choi EK
    Yonsei Med J; 2019 Mar; 60(3):277-284. PubMed ID: 30799590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Uninterrupted administration of edoxaban vs vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation: Rationale and design of the ELIMINATE-AF study.
    Hohnloser SH; Camm J; Cappato R; Diener HC; Heidbuchel H; Lanz HJ; Mont L; Morillo CA; Smolnik R; Yin OQP; Kautzner J
    Clin Cardiol; 2018 Apr; 41(4):440-449. PubMed ID: 29663464
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency and Outcomes of Reduced Dose Non-Vitamin K Antagonist Anticoagulants: Results From ORBIT-AF II (The Outcomes Registry for Better Informed Treatment of Atrial Fibrillation II).
    Steinberg BA; Shrader P; Pieper K; Thomas L; Allen LA; Ansell J; Chan PS; Ezekowitz MD; Fonarow GC; Freeman JV; Gersh BJ; Kowey PR; Mahaffey KW; Naccarelli GV; Reiffel JA; Singer DE; Peterson ED; Piccini JP;
    J Am Heart Assoc; 2018 Feb; 7(4):. PubMed ID: 29453305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.